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Football season in the US ended
with the Super Bowl, and baseball
season doesn’t start until April. But
readers yearning for lusty
competition were not disappointed
in mid-February. Please welcome
genomics as the latest blood sport. 
The sparring began well before
the Celera Stalkers and the Public
Puritans had their big match — a
news conference on 12 February in
Washington DC. The whole week
before, team members were trading
barbs (on an embargoed basis, of
course). Deciphering the human
genome is a noble and lofty
enterprise. But there’s nothing quite
like a fight to liven up the
newspaper. 
Eric Lander, from the Whitehead
Institute, headed the offense for the
Public. He told the Washington Post,
for one, that Celera’s whole-genome
shotgun sequencing was a failure, to
be reserved for special circumstances. 
Deciphering the human genome
is a noble and lofty enterprise.
But there’s nothing quite like a
fight to liven up the newspaper
“Maybe we don’t care about a
perfect sequence of, say, the
platypus,” Lander told the Post.
“We’ve got the human right. I think
the mouse we want to get right. But
the wombat, the platypus, maybe
pigs or something — there may be a
lot of value in doing things like this.” 
Venter’s reply? Too bad his
rivals had, “got their panties in a
gather” once again over the issue of
whose technique is better. “Eric
Lander is obviously bothered by
Celera’s success. He’s playing with
half-truths and innuendos. I’m
getting so I really don’t care what his
opinion is.” 
The Los Angeles Times wrote an
early Valentine to the Public, by
quoting a stream of partisans allied
against Venter. “He represented his
idea as a revolutionary approach and
that the public effort was too dumb
to recognize that it works… But the
whole-genome approach failed,”
Philip Green from the University of
Washington told the Times. “What
they did was give up,” added Green’s
colleague Maynard Olson. Celera
had a limited rebuttal in that story.
But in other news accounts, Celera
countered that the Public’s effort is
inferior because it currently has
many bits of the sequence out of
order and not oriented properly. 
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One difficulty with a sport like
this is the average reader (and even
the above-average reporter) finds the
all-important details even more
baffling than baseball’s infield fly rule. 
The Wall Street Journal took a
sensible approach to sorting all this
out: It looked at what the
marketplace is doing. Institutions are
plunking down $10,000 or more to
gain access to Celera’s database.
Presumably they’re not all simply
trying to keep up with the Joneses.
“For more than a year, J. Craig
Venter has boasted that his upstart
company, Celera Genomics Group,
would produce a better, more user-
friendly map of the human than
legions of taxpayer-funded
academics who had almost a decade-
long head start. It turns out for all his
braggadocio, Dr. Venter was right.” 
The Journal quotes several
scientists, largely from the world of
business, singing the praises of the
Celera database. Among the
converted: Douglas Williams, chief
technology officer of Immunex, a
biotechnology company in Seattle.
He said Celera is ahead of Genbank,
the repository for the public effort.
“How much? I don’t know,” he told
the Journal. “From where I stand,
even if it’s only one or two days, it’s
important. This is all about getting
there first.” 
The Wall Street Journal’s editorial
page openly sneered at the public
effort. “For years, advocates of public
funding for basic research and
technology have argued that only the
government possesses the resources,
and even the moral
disinterestedness, to take on these
long-term projects, pointing to the
Internet or satellite technology as
evidence. But with the success of
Dr. Venter’s enterprise, this
argument has at last been exposed as
a fallacy. It’s time governments —
and taxpayers — take notice of this
new reality.” 
But reality, according to the
Wellcome Trust, is actually quite
different. “The greater part of the
data for Celera’s assemblies (DNA 
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sequences) comes from the Human
Genome Project,” the trust said in a
statement quoted in The Independent
(London). “Despite the benefit,
Celera’s assembly is only comparable
with that of the HGP and is
dependent upon it. Far from
‘winning the race’, as they have
claimed, and many commentators
have believed, their methodology has
been found wanting.” 
The big face-to-face showdown
on 12 February was, by comparison,
a letdown. Venter and Lander sat at
the same rostrum but denied the
banks of television cameras any
overt conflict. The Public
Puritans were satisfied to repeat the
mantra, ‘our data are free to all,’ while
the Celera Stalkers mentioned
offhand — oh, we’ve just about
finished the mouse. Both these
digs scored points with the
cognoscenti. But if genomics is
ever going to make it on ABC’s
Wide World of Sports, it’ll have to do
better than that. 
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